Compare United States Copper Index Fund (CPER) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
United States Copper Index Fund vs Zimmer Biomet Holdings Inc — how do they compare? United States Copper Index Fund trades at $40.34, while Zimmer Biomet Holdings Inc trades at $95.61 (market cap $18.55B). The key difference: Zimmer Biomet Holdings Inc pays a 0.99% dividend while United States Copper Index Fund pays none, and United States Copper Index Fund is trading nearer its 52-week high, Zimmer Biomet Holdings Inc nearer its low. Which is the better fit depends on your goals.
| CPER | ZBH | |
|---|---|---|
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $40.85 | $107.71 |
52-Week Low | $27.57 | $79.58 |
Market Cap | — | $18.55B |
Enterprise Value | — | $25.61B |
Dividend Yield | — | 0.99% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CPER (United States Copper Index Fund) trades at $40.345, up 0.41% with a bullish technical signal supported by moving averages. The copper market faces supply constraints from Chilean weather disruptions while AI and electrification demand drives prices to record highs. Recent news highlights copper's structural bull case with Citi targeting $15,000/tonne by year-end.
Copper's fundamental outlook remains strong due to AI infrastructure demand and supply constraints, though substitution risks and geopolitical tensions present headwinds. The ETF offers pure copper exposure amid favorable analyst sentiment, with technical indicators suggesting continued upward momentum near key resistance levels.
ZBH trades at $97.78, up 1.27% today, with a bullish technical outlook supported by moving averages and recent earnings beats. The company reported Q2 2026 EPS of $2.07, exceeding expectations, and raised its 2026 outlook. Revenue growth remains steady at 4.8% year-over-year, though net income margin has moderated from 2023 peaks. Analyst consensus is a 'Buy' with a $103.56 price target, indicating modest upside potential from current levels.
The stock offers a balanced risk-reward profile with solid fundamentals and positive momentum, but faces headwinds from margin pressure and rising debt levels. Investors should weigh the strong institutional support and consistent earnings performance against competitive pressures and macroeconomic uncertainties affecting the medtech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About United States Copper Index Fund
CPER is a commodity ETF that tracks the price of copper futures via the SummerHaven Copper Index. It provides direct exposure to the 'red metal' using a rules-based strategy to select futures contracts, making it a key tool for hedging or betting on industrial growth and electrification.
Read more on CPER →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
